185 related articles for article (PubMed ID: 37783509)
1. Impact of ACEIs and ARBs-related adverse drug reaction on patients' clinical outcomes: a cohort study in UK primary care.
Insani WN; Whittlesea C; Ju C; Man KK; Adesuyan M; Chapman S; Wei L
Br J Gen Pract; 2023 Nov; 73(736):e832-e842. PubMed ID: 37783509
[TBL] [Abstract][Full Text] [Related]
2. Statin-related adverse drug reactions in UK primary care consultations: A retrospective cohort study to evaluate the risk of cardiovascular events and all-cause mortality.
Insani WN; Whittlesea C; Ju C; Man KKC; Alwafi H; Alsharif A; Chapman S; Wei L
Br J Clin Pharmacol; 2022 Nov; 88(11):4902-4914. PubMed ID: 35695656
[TBL] [Abstract][Full Text] [Related]
3. Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers in Patients Without Heart Failure? Insights From 254,301 Patients From Randomized Trials.
Bangalore S; Fakheri R; Toklu B; Ogedegbe G; Weintraub H; Messerli FH
Mayo Clin Proc; 2016 Jan; 91(1):51-60. PubMed ID: 26763511
[TBL] [Abstract][Full Text] [Related]
4. Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on cardiovascular events in patients with heart failure: a meta-analysis of randomized controlled trials.
Tai C; Gan T; Zou L; Sun Y; Zhang Y; Chen W; Li J; Zhang J; Xu Y; Lu H; Xu D
BMC Cardiovasc Disord; 2017 Oct; 17(1):257. PubMed ID: 28982370
[TBL] [Abstract][Full Text] [Related]
5. ACE Inhibitor Benefit to Kidney and Cardiovascular Outcomes for Patients with Non-Dialysis Chronic Kidney Disease Stages 3-5: A Network Meta-Analysis of Randomised Clinical Trials.
Zhang Y; He D; Zhang W; Xing Y; Guo Y; Wang F; Jia J; Yan T; Liu Y; Lin S
Drugs; 2020 Jun; 80(8):797-811. PubMed ID: 32333236
[TBL] [Abstract][Full Text] [Related]
6. Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on all-cause mortality, cardiovascular deaths, and cardiovascular events in patients with diabetes mellitus: a meta-analysis.
Cheng J; Zhang W; Zhang X; Han F; Li X; He X; Li Q; Chen J
JAMA Intern Med; 2014 May; 174(5):773-85. PubMed ID: 24687000
[TBL] [Abstract][Full Text] [Related]
7. Association Between Renin-Angiotensin-Aldosterone System Inhibitors and Clinical Outcomes in Patients With COVID-19: A Systematic Review and Meta-analysis.
Baral R; Tsampasian V; Debski M; Moran B; Garg P; Clark A; Vassiliou VS
JAMA Netw Open; 2021 Mar; 4(3):e213594. PubMed ID: 33787911
[TBL] [Abstract][Full Text] [Related]
8. A systematic review and meta-analysis of the use of renin-angiotensin system drugs and COVID-19 clinical outcomes: What is the evidence so far?
Kurdi A; Abutheraa N; Akil L; Godman B
Pharmacol Res Perspect; 2020 Dec; 8(6):e00666. PubMed ID: 33084232
[TBL] [Abstract][Full Text] [Related]
9. Incidence of and Risk Factors for Severe Adverse Events in Elderly Patients Taking Angiotensin-Converting Enzyme Inhibitors or Angiotensin II Receptor Blockers after an Acute Myocardial Infarction.
Fang G; Annis IE; Farley JF; Mahendraratnam N; Hickson RP; Stürmer T; Robinson JG
Pharmacotherapy; 2018 Jan; 38(1):29-41. PubMed ID: 29059475
[TBL] [Abstract][Full Text] [Related]
10. A Retrospective Study from 2 Centers in China on the Effects of Continued Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers in Patients with Hypertension and COVID-19.
Wang Z; Zhang D; Wang S; Jin Y; Huan J; Wu Y; Xia C; Li Z; Qi X; Zhang D; Han X; Zhu X; Qu Y; Wang Q
Med Sci Monit; 2020 Sep; 26():e926651. PubMed ID: 32969367
[TBL] [Abstract][Full Text] [Related]
11. Higher versus lower doses of ACE inhibitors, angiotensin-2 receptor blockers and beta-blockers in heart failure with reduced ejection fraction: Systematic review and meta-analysis.
Turgeon RD; Kolber MR; Loewen P; Ellis U; McCormack JP
PLoS One; 2019; 14(2):e0212907. PubMed ID: 30817783
[TBL] [Abstract][Full Text] [Related]
12. Impact of renin angiotensin system inhibitor on 3-year clinical outcomes in acute myocardial infarction patients with preserved left ventricular systolic function: a prospective cohort study from Korea Acute Myocardial Infarction Registry (KAMIR).
Kim KH; Choi BG; Rha SW; Choi CU; Jeong MH;
BMC Cardiovasc Disord; 2021 May; 21(1):251. PubMed ID: 34020593
[TBL] [Abstract][Full Text] [Related]
13. The impact of the 'Better Care Better Value' prescribing policy on the utilisation of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for treating hypertension in the UK primary care setting: longitudinal quasi-experimental design.
Baker A; Chen LC; Elliott RA; Godman B
BMC Health Serv Res; 2015 Sep; 15():367. PubMed ID: 26359265
[TBL] [Abstract][Full Text] [Related]
14. Nurse-led titration of angiotensin converting enzyme inhibitors, beta-adrenergic blocking agents, and angiotensin receptor blockers for people with heart failure with reduced ejection fraction.
Driscoll A; Currey J; Tonkin A; Krum H
Cochrane Database Syst Rev; 2015 Dec; 2015(12):CD009889. PubMed ID: 26689943
[TBL] [Abstract][Full Text] [Related]
15. Comparative Effectiveness of Combination Therapy with Statins and Angiotensin-Converting Enzyme Inhibitors versus Angiotensin II Receptor Blockers in Patients with Coronary Heart Disease: A Nationwide Population-Based Cohort Study in Korea.
Lee J; Lee S
Pharmacotherapy; 2018 Nov; 38(11):1095-1105. PubMed ID: 30225928
[TBL] [Abstract][Full Text] [Related]
16. Impact of in-hospital discontinuation with angiotensin receptor blockers or converting enzyme inhibitors on mortality of COVID-19 patients: a retrospective cohort study.
de Abajo FJ; Rodríguez-Miguel A; Rodríguez-Martín S; Lerma V; García-Lledó A;
BMC Med; 2021 May; 19(1):118. PubMed ID: 33980231
[TBL] [Abstract][Full Text] [Related]
17. Comparative risk for angioedema associated with the use of drugs that target the renin-angiotensin-aldosterone system.
Toh S; Reichman ME; Houstoun M; Ross Southworth M; Ding X; Hernandez AF; Levenson M; Li L; McCloskey C; Shoaibi A; Wu E; Zornberg G; Hennessy S
Arch Intern Med; 2012 Nov; 172(20):1582-9. PubMed ID: 23147456
[TBL] [Abstract][Full Text] [Related]
18. Prognostic impact of angiotensin-converting enzyme inhibitors and angiotensin receptors blockers in esophageal or gastric cancer patients with hypertension - a real-world study.
Li PC; Huang RY; Yang YC; Hsieh KP; Yang YH
BMC Cancer; 2022 Apr; 22(1):430. PubMed ID: 35443635
[TBL] [Abstract][Full Text] [Related]
19. Updates on the treatment of essential hypertension: a summary of AHRQ's comparative effectiveness review of angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and direct renin inhibitors.
Powers B; Greene L; Balfe LM
J Manag Care Pharm; 2011 Oct; 17(8 Suppl):S1-14. PubMed ID: 22088101
[TBL] [Abstract][Full Text] [Related]
20. Influence of angiotensin converting enzyme inhibitors/angiotensin receptor blockers on the risk of all-cause mortality and other clinical outcomes in patients with confirmed COVID-19: A systemic review and meta-analysis.
Jia N; Zhang G; Sun X; Wang Y; Zhao S; Chi W; Dong S; Xia J; Zeng P; Liu D
J Clin Hypertens (Greenwich); 2021 Sep; 23(9):1651-1663. PubMed ID: 34320275
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]